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Abstract
Summary Fracture Liaison Services are recommended to deliver best practice in secondary fracture prevention. This modified
Delphi survey, as part of the iFraP (Improving uptake of Fracture Prevention drug Treatments) study, provides consensus
regarding tasks for clinicians in a model Fracture Liaison Service consultation.
Purpose The clinical consultation is of pivotal importance in addressing barriers to treatment adherence. The aim of this study
was to agree to the content of the ‘model Fracture Liaison Service (FLS) consultation’ within the iFraP (Improving uptake of
Fracture Prevention drug Treatments) study.
Methods A Delphi survey was co-designed with patients and clinical stakeholders using an evidence synthesis of current
guidelines and content from frameworks and theories of shared decision-making, communication and medicine adherence.
Patients with osteoporosis and/or fragility fractures, their carers, FLS clinicians and osteoporosis specialists were sent three
rounds of the Delphi survey. Participants were presented with potential consultation content and asked to rate their perception of
the importance of each statement on a 5-point Likert scale and to suggest new statements (Round 1). Lowest rated statements
were removed or amended after Rounds 1 and 2. In Round 3, participants were asked whether each statement was ‘essential’ and
percentage agreement calculated; the study team subsequently determined the threshold for essential content.
Results Seventy-two, 49 and 52 patients, carers and clinicians responded to Rounds 1, 2 and 3 respectively. One hundred twenty-
two statements were considered. By Round 3, consensus was reached, with 81 statements deemed essential within FLS consul-
tations, relating to greeting/introductions; gathering information; considering therapeutic options; eliciting patient perceptions;
establishing shared decision-making preferences; sharing information about osteoporosis and treatments; checking
understanding/summarising; and signposting next steps.
Conclusions This Delphi consensus exercise has summarised for the first time patient/carer and clinician consensus regarding
clearly defined tasks for clinicians in a model FLS consultation.
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Introduction
In the UK, Fracture Liaison Services (FLSs) are recommend-
ed to deliver best practice in secondary fracture prevention [1].
These services are typically Allied Health Professional (AHP)
or nurse-led and systematically identify patients aged 50 years
and over who have experienced a fragility fracture [2].
Evidence-based medications include bisphosphonates, as rec-
ommended by National Institute for Health and Care
Excellence (NICE) as the first-line therapy for patients with
osteoporosis (underlying bone fragility) and/or high fracture
risk [3]. Bisphosphonates are inexpensive, cost-effective and
readily available and reduce fracture risk by 20–70% (depen-
dent on fracture site) [3].
Clinical Standards for FLSs [4] comprise four aspects of
care in the patient pathway: identification, investigation, pro-
viding information and support and intervention. These stan-
dards recommend follow-up to support adherence to treat-
ment, as bisphosphonate therapy adherence is known to be
low and limits treatment effectiveness. National audit results,
which monitor performance against these UK standards, indi-
cate that when bisphosphonates are recommended in FLSs,
long-term patient adherence is no better than in non-
specialist settings and possibly worse. 2018 data indicates that
of those patients in whom FLSs recommended starting treat-
ment, only 23% remained adherent at 12 months [2].
Low adherence to osteoporosis treatment globally and the
high rate of consequent fragility fractures have been described
as the ‘osteoporosis crisis’ [5, 6]. Key contributing factors to
low adherence rates include patient (and primary care clini-
cians’) concerns about harms, uncertainty about treatment ben-
efits and lack of clarity about what constitutes treatment suc-
cess [7]. This highlights the importance of clinicians under-
standing and using relevant evidence in the clinical consulta-
tion to clearly communicate risks. Clinicians need to feel con-
fident discussing risks of poor disease outcome (prognosis)
and the harms and benefits relating to treatment options and
facilitating patients to articulate their values and preferences to
promote informed decision-making [8]. The Royal (previously
National) Osteoporosis Society (ROS) recommends the provi-
sion of information as a core component of management [9].
Evidence across a range of conditions and contexts demon-
strates that effective use of information within a consultation
can increase patient satisfaction, facilitate participation in the
consultation and promote trust [8]. Importantly, evidence also
suggests that effective use of communication may improve
patients’ treatment initiation rates [10] and strengthen their
commitment to preventative treatments [11].
The iFraP study (improving uptake of Fracture Prevention
drug treatment) aims to develop and evaluate a theoretically
informed complex consultation intervention to facilitate in-
formed decision-making about fracture prevention treatment,
with a long-term aim of improving informed medication ad-
herence [12]. iFraP includes a computerised decision support
tool (CDST) and clinician training package to support clinical
decision-making and patient-clinician communication about
the patient’s diagnosis, medication options (e.g.
bisphosphonates) and lifestyle management for bone health
(e.g. smoking, physical activity).
This paper reports findings from a modified Delphi survey
with patients, carers and clinicians that aimed to agree the
content of the iFraP ‘model FLS consultation’. This study
took place in the context of the iFraP intervention develop-
ment (iFraP-D) study designed to define the content and the-
oretical basis for the iFraP intervention [12].
Methods
Co-design of the Delphi survey
A modified, three-round, online Delphi survey (Fig. 1) [13]
was co-designed in partnership with members of the iFraP
stakeholder group and patient advisory group (PAG), with
the aim to develop a survey with a common, understandable
language for patients, carers and clinicians. The stakeholders
included FLS nurses, pharmacists, GPs, osteoporosis special-
ists (representing elderly care, rheumatology and metabolic
bone medicine) and representatives from the ROS and
Health Literacy UK, supported by a behaviour change expert,
with expertise in medicine adherence. Patient representation
was a key element to ensure the final intervention remained
targeted at patient priorities. Six (4:2 female/male) patients
with experience of osteoporosis and/or fractures (supported
by a Patient and Patient Involvement and Engagement
(PPIE) support worker) attended a dedicated PAG, with two
PAG members attending stakeholder meetings.
Two stakeholder meetings were conducted to interpret the
findings of the evidence synthesis (see Statement generation)
in the context of FLS and discuss example explanations,
which formed the basis of statement wording. The PAG con-
tributed to the design of the study, including (i) how best to
recruit and explain the Delphi survey to patients/carers; (ii)
design of the survey, by developing clinical vignettes and
(re)wording statements; and (iii) and piloting. Two PAG
members also attended survey analysis and interpretation
meetings (Rounds 1 and 2) to consider whether statements
should be removed or be amended and helped to reword state-
ments (see Data collection and analysis). To promote trans-
parency and address hypothetical concerns of bias, there was
   58 Page 2 of 17 Arch Osteoporos           (2021) 16:58 
Round 1
Statements with a 
combined score of < 4
Statements scoring < 4 by 
either patients/carers or 
clinicians









PPIE Patient and Public Involvement and Engagement; NICE National Institute for Health 
and Care Excellence
Progressed
Reviewed by subgroup of 
the study team (+PPIE)
Statements with a score in the bottom 
quartile by patient/carer and/or clinician 
participants
Reviewed by subgroup of the study team 
(+PPIE)
Amended Progressed
Study team subgroup decided appropriate threshold for 
consultation tasks to be considered ‘essential’ or ‘optional’
Statements at or below the 
threshold
Statements above the 
threshold
Reviewed by subgroup of 
study team (+PPIE) and 
experts





Statements generated from: osteoporosis clinical guidelines; NICE guidance relating to 
patient experience and medicines adherence; theories and frameworks relating to consulting, 
medicines adherence, shared decision-making and using decision aids; emerging findings 
from iFraP-D
Round 2
Fig. 1 Overview of Delphi methods
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clear documentation of the statements before and after each
time-point at which the PAG provided input so that the influ-
ence of the PAG was recorded and reported clearly.
Furthermore, discussion with the PAG on statement inclusion
(in conjunction with a clinician and 2 social scientists) was
informed not only by PAG views but also underpinning the-
ory, other emergent findings in iFraP-D (e.g. focus groups),
explanatory Delphi free-text comments, whether the item was
scored low by patients/carers or clinicians and responses to
other similar items in the Delphi.
Delphi participants and recruitment
Delphi surveys aim to recruit expert participants [14]. In the
context of FLS consultations, experts included:
(1) Patients with osteoporosis and/or fragility fractures and/
or their carers recruited via the ROS supporters network
(2) Clinicians with experience of consulting with patients,
where fracture risk is calculated and fracture prevention
treatments are recommended (e.g. endocrinologists,
rheumatologists and FLS clinicians), recruited via ROS
healthcare professional mailing lists and the study team’s
clinical networks
Statement generation
The Delphi approach is described as ‘modified’ as in the first
round participants were presented with a list of statements to
consider rather than generating their own list. However, par-
ticipants had the opportunity to suggest additional consulta-
tion tasks.
Each ‘statement’ corresponded to a clinician task for the
consultation and included clinician decision-making tasks and
considerations, eliciting information, giving information, ex-
ample explanations and hypothetical use of the CDST.
Statements were generated from a number of sources,
including:
(1) Clinical guidelines for the assessment and management
of osteoporosis/fragility fractures that refer to tasks for
the clinician in the consultation [3, 15–25].
(2) NICE guidance (not specific to osteoporosis) relating to
the conduct of the consultation, in enhancing patient ex-
perience and medicine adherence [26, 27].
(3) Theories and frameworks relating to consulting, medi-
cine adherence, shared decision-making and using deci-
sion aids [28–30].
(4) Emerging findings from iFraP-D, i.e. stakeholder and
PAG discussions, and qualitative findings from focus
groups. Additionally, Delphi free-text comments
provided by participants in Round 1 generated additional
statements for inclusion in Round 2.
Statements derived from UK and European clinical guide-
lines were sourced from an evidence synthesis exercise which
included a systematic search, quality appraisal and data ex-
traction process (conductedMarch–June 2019, more details in
Supplementary Material 1). These statements were used in
Round 1. Statements derived from theory, frameworks and
emerging findings, fed into both Rounds 1 and 2.
Extracted statements from the evidence synthesis were
organised into stages of the consultation. To this end, a frame-
work for the consultation was developed, informed by the
phases identified in the evidence synthesis, and underpinning
theory, frameworks of shared decision-making and principles
of health literacy [28, 30–32]. The framework included a se-
ries of stages and tasks for the clinician to progress through
during the consultation, including gathering information, con-
sidering therapeutic options and eliciting patient knowledge,
through to summarising and signposting (Table 1).
Clinical vignettes orientated the participant to the stage of
the consultation and provided context to statements that only
applied to patients with particular characteristics, e.g. a patient
with bone mineral density in the osteopenic range or a patient
declining treatment.
Data collection and analysis
Consent was captured on the first page of the online survey.
Participants that provided consent to Round 1 were emailed
Rounds 2 and 3 by the study team. One reminder to complete
the survey was sent at approximately 2 weeks for each survey
round. Invitations were sent to 193 patients/carers (via the
ROS supporters network) and 194 clinicians (176 via the
ROS mailing lists and 18 by the study team to their clinical
networks), anticipating an approximate 40% response rate to
Round 1, and further drop out at Rounds 2 and 3. Our aim was
to achieve an approximate final sample of 15 patients/carers
and 15 clinician responders to Round 3.
Round 1 Participants were asked to rate their perception of the
importance of each statement on a 5-point Likert scale, rang-
ing from 5 ‘very important, should definitely be included’, to
1 ‘not important, should definitely not be included’.
Participants also had the opportunity to indicate if the state-
ment was unclear or to add additional statements for the con-
sultation in free-text boxes.
Mean response scores were calculated for patients/carers
and clinicians separately and combined. Statements with a
combined mean score of less than 4 (important, should prob-
ably be included) were removed after Round 1. Statements
that scored less than 4 by either patients/carers or clinicians
were reviewed by a sub-group of the study team (CJ, ZP, LB),
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with two PAGmembers, to consider whether amendment was
required [33]. This discussion was informed by underpinning
theory, other emergent findings in iFraP-D (e.g. focus groups),
PAG experiences and views, explanatory Delphi free-text
comments, whether the item was scored low by patients/
carers or clinicians and responses to other similar items in
the Delphi. Statements were amended by changes to the con-
textual vignette or rewording the statement.
Statements that scored equal to or greater than 4 by clini-
cians and patients/carers progressed to Round 2. Statements
that were indicated or described as unclear in free-text
underwent minor rewording, with the PAG.
Round 2 Round 2 included statements that had progressed
fromRound 1, and new statements from free-text Delphi state-
ments, and from iFraP-D emerging findings, as above. In the
Round 2 survey, participants were shown mean scores of im-
portance fromRound 1 and asked to re-rate their perception of
the importance of each statement on the same 5-point Likert
scale. Free-text boxes were included for participants to give
reasons or state anything that was unclear.
Mean response scores were calculated for patients/carers
and clinicians separately and combined. Mean combined
scores were ranked, with statements in the top 3 of 4 quartiles
progressing to Round 3, as a commonly used Delphi analyti-
cal approach [34]. A small number of statements were deemed
‘considerations’ rather than tasks, which would not make
sense with the amended survey in Round 3 (e.g. ‘the discus-
sion about the benefits and risks of osteoporosis medicines is
best undertaken face-to-face’). For these statements, consen-
sus was accepted at Round 2 instead of Round 3. Statements
with a patient/carer and/or clinician score in the lowest quartile
were reviewed by the study sub-group and PAG members, as
to whether the statement should be removed, proceed or be
amended, informed by the considerations described in Round
1.
Round 3 Round 3 included statements that had progressed
from Round 2, but no new statements. Unlike Rounds 1 and
2, in Round 3, participants were asked whether the statement
was essential in a time-limited consultation of 30min to reflect
the typical length of FLS appointments. Participants rated
each statement as ‘essential’ or ‘optional’.
Combined patient/carer and clinician percentage
agreement was calculated as the percentage of partici-
pants rating each statement as ‘essential’. Statements
were ranked according to combined percentage agree-
ment. The study sub-group met to review the ranking
and consider the appropriate threshold for essential vs
optional tasks, which was not defined a priori. Tasks
falling below the threshold were further reviewed with
the broader study team, including experts in medicine
adherence and health literacy. The purpose of this re-
view was to consider if there was appropriate theoretical
justification to re-consider any of the optional state-
ments, as essential, in accordance with previous Delphi
studies that involved discussion groups to provide com-
ment on the inclusion or exclusion of statements [35,
36].
Finally, the essential statements were refined into a shorter
list by the study team, based on the nature of the task (e.g.
explaining, asking, considering) and stage of the consultation.
Table 1 Example statements for
each consultation stage Consultation stage/clinician task Example statement
1. Greeting/introduction The clinician should ask what the patient is expecting from the
appointment (consultation)
2. Gathering information The clinician should ask the patient how their fracture affected
them
3. Considering therapeutic options The clinician should, if drug treatment (medicine) is needed, offer
a tablet bisphosphonate first
4. Eliciting patient perceptions The clinician should ask the patient what they know about
osteoporosis and fractures
5. Establishing shared decision-making
preferences
The clinician should establish what involvement in
decision-making the patient would like
6. Sharing information about condition The clinician should show and explain the bone density scan
results
7. Sharing information about treatment—
lifestyle and drugs
The clinician should explain common or severe side effects
8. Checking understanding and
summarise
The clinician should check whether the patient knows the benefits
and risks
9. Signposting next steps The clinician should give the patient information about local
support groups and services
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Results
Seventy-two patients/carers and clinicians responded in
Round 1 (23% patient/carer response rate; 14% clinician re-
sponse rate), which reduced to 49 and 52 in Rounds 2 and 3,
respectively (Fig. 2). Characteristics of participants in each
round in Table 2 show that there were more patient/carer par-
ticipants than clinicians in all three rounds (45, 39 and 37,
compared with 27, 10 and 15, respectively). The majority of
patients/carers were female, with the largest proportion aged
between 71 and 80 years old, irrespective of survey round. All
clinicians were female and most were nurses or AHPs.
A total of 122 statements were considered, each describing
clinician decision-making tasks and considerations. In Round 2,
seven statements were accepted as reaching consensus. In Round
3, combined percentage agreement scores were ranked, with
scores ranging from 33 to 100%. The study sub-group set the
threshold for inclusion as essential in a time-limited consultation
as > 75% agreement. Sixty-nine (78% of Round 3 statements)
statements in Round 3 were rated over this threshold and 19
(22%) statements fell below. Of these 19 statements, five were
reconsidered as essential by the study team, with theoretical
justification (detailed below). The flow of statements and
decision-making is detailed in Supplementary Figure 1. The final
statements of essential (n = 81) and optional (n = 14) consultation
content and their final Round 3 percentage agreement scores are
detailed in Table 3, with the 18 refined statements describing
essential consultation tasks in Table 4. Scoring from Rounds
1–2 is available in Supplementary Table 2.
A narrative relating to the statements describing tasks
which were deemed essential, optional or not relevant
(removed) within each stage of the consultation is presented
below, using excerpts from the participants’ free-text com-
ments to explain the decision-making; theoretical justification
of any re-classified statements is also detailed.
Stage 1: Greeting/introduction
Essential Among both patient/carer and clinician participants,
there were high levels of agreement on the importance of
explaining the aim of the FLS appointment and the clinician’s
ability to calculate fracture risk.
A further task relating to ascertaining patient expecta-
tions of the appointment achieved 60% agreement to
Fig. 2 Recruitment flowchart
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include in a time-limited consultation and fell below the
threshold for inclusion. The study team deemed this essen-
tial, as other findings in iFraP-D illustrated that patients
were often unprepared for FLS, and eliciting and address-
ing patient expectations is an important foundation for
shared decision-making.
Optional Explaining the limitations of fracture risk assess-
ment, a task identified from clinical guidelines, received
62% agreement.
Stage 2: Gathering information
Essential Both patients/carers and clinicians had high agree-
ment on the need for questions related to eliciting medical
history, including recent and previous fracture details, diet
and lifestyle, risk factors for falls, fractures and osteoporosis
and signs of vertebral fracture. Further investigations includ-
ing dual-energy X-ray absorptiometry (DXA), blood tests and
imaging of the spine were also identified as essential, where
appropriate.
Optional In Round 3, ‘observe’ (reworded from earlier rounds
due to concern about the term ‘examine’) the patient for signs
of spinal fractures had lower agreement among clinicians
(60%) than patients/carers (76%). Free-text comments re-
vealed doubts about the applicability of physical examination
to a nurse’s role and about the reliability of ‘observation’ in
detecting fractures.
Not relevant Asking about menopausal symptoms and
conducting a physical examination as part of a falls assess-
ment were removed in Rounds 1–2. Statements questioning
the patient about what was important to them (e.g. ‘the clini-
cian should find out what is important and what matters to the
patient (e.g. hobbies, work, health, family)’) were also re-
moved. Free-text comments questioned the relevance and
specificity of these questions.
Stage 3: Considering therapeutic options
Essential Consensus was reached in Round 2 about the use of
national guidelines to make clinical decisions, with the caveat
that clinicians need to be aware of circumstances in which
fracture risk may be underestimated by commonly used tools
such as FRAX. The use of oral bisphosphonates as a first-line
therapy was endorsed, except when patients had contraindica-
tions or memory problems.
Stages 4 and 5: Eliciting patient perceptions and
establishing shared decision-making preferences
Essential Patients/carers and clinicians agreed that it was es-
sential to understand the patient’s perceptions of osteoporosis
and drug treatment before giving information.
Despite being rated as important by patients/carers
and clinicians in Rounds 1 and 2, only 68% of
patients/carers agreed that it is essential for clinicians
to establish what involvement the patient would like to
have in making decisions about medicines in a time-
limited consultation. The study team felt this was essen-
tial due to the fundamental importance of this task in
determining the nature of subsequent conversations
about treatment options, using the principles of shared
decision-making.
Optional Asking about patients’ perceptions of the strength of
their bone, their views of prescription medicine generally and
Table 2 Participant characteristics
Patient/carer
Round 1 Round 2 Round 3
Total n 45 39 37
Gender female n (%) 41 (91) 35 (90) 33 (89)
Age
21–30 0 (0) 0 (0) 0 (0)
31–40 1 (2) 1 (3) 1 (3)
41–50 0 (0) 0 (0) 0 (0)
51–60 2 (4) 3 (8)* 1 (3)
61–70 16 (36) 14 (36) 15 (41)
71–80 21 (47) 15 (39) 16 (43)
81–90 5 (11) 6 (15) 4 (11)
Clinician
Round 1 Round 2 Round 3
Total n 27 10 15
Gender female n (%) 27 (100) 10 (100) 15 (100)
Age
21–30 1 (4) 0 (0) 1 (7)
31–40 4 (15) 1 (10) 2 (13)
41–50 8 (30) 4 (40) 3 (20)
51–60 9 (33) 2 (20) 4 (27)
61–70 4 (15) 2 (20) 3 (20)
71–80 0 (0) 0 (0) 1 (7)*
81–90 1 (4) 1 (10) 1 (7)
Occupation
Allied health professional 1 (4) 0 (0) 1 (7)
FLS nurse 10 (37) 4 (40) 5 (33)
Metabolic bone specialist 1 (4) 1 (10) 1 (7)
OP specialist nurse 10 (37) 3 (30) 3 (20)
Rheumatologist 1 (4) 0 (0) 1 (7)
Other 4 (15) 2 (20) 4 (27)
*n = 2 participants self-reported as a patient or clinician differently in
Delphi survey rounds
FLS Fracture Liaison Service, OP osteoporosis
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Table 3 Statements describing tasks classified as essential or optional
Statement Round 3
% of participants agreeing that each statement
was ‘essential in a time-limited consultation’
≤7 5% italics









find out what the patient is expecting from the appointment (consultation) 51% 80% 60%†
explain to their patient that the aim of the appointment is to think about what steps they could take to
improve bone health and try and prevent further broken bones
97% 100% 98%
explain that the aim is also to investigate whether the patient has osteoporosis, or weaker bones, that
may be more likely to break after a minor trip or fall
92% 100% 94%
explain that the patient’s risk of breaking bones (fracture risk) in the future can be estimated 76% 87% 79%
tell the patient the limitations of estimating her risk of breaking a bone (fracture risk)* 54% 80% 62%
Stage 2: Gathering information
The clinician should ask the patient…
about their general health 92% 94% 92%
how the fracture impacted on their life 95% 67% 87%
about their risk factors for breaking a bone (fracture) which may include smoking, family history,
previous fractures, alcohol, medical conditions, medications, etc.
97% 100% 98%
how their broken wrist happened 76% 100% 83%
questions to find out if the patient is at risk of falls 81% 100% 87%
about their other health conditions to identify causes of osteoporosis 87% 100% 90%
about their other health conditions to find out which medicines might be unsuitable 97% 93% 96%
if they have had back pain, or got shorter (height loss) (signs that they may have had fractures in their
spine)
87% 87% 87%
questions about their diet and calcium intake 92% 100% 94%
The clinician should…
observes the patient’s spine to look for signs of fractures (broken bones) or curvature* 76% 60% 71%
if appropriate, recommend and arrange a scan to assess the patient's bone density (strength), which will
diagnose osteoporosis, if it is present
100% 100% 100%
tell the patient why the scan is being recommended, what the scan involves and how it will affect them 87% 100% 90%
arrange further imaging (such as x-rays and other tests) of the spine to look for broken bones, if
appropriate
84% 73% 81%
use a website based scoring system (e.g. FRAX) to estimate the patient’s individual risk of breaking a
bone (fracture)*
68% 87% 73%
if appropriate, recommend and arrange blood tests to rule out conditions that can make broken bones
and/or osteoporosis more likely
81% 100% 87%
Stage 3: Considering therapeutic options
The clinician should…
use national guidelines (recommendations and guidance based on evidence) to decide which patients
should be offered drug treatment (medicine) to prevent further fractures (broken bones)
N/A N/A N/A
be aware, and take into account, the circumstances in which the estimated fracture risk may be less
accurate (e.g. for patients on high-dose steroids)
N/A N/A N/A
not offer tablet bisphosphonate medicines to patients who have existing problems swallowing, have
severe indigestion or can’t take tablets
N/A N/A N/A
not offer tablet bisphosphonate medicines to patients who have memory problems (e.g. dementia),
unless they have support with taking medicines
N/A N/A N/A
Stage 4: Eliciting patient perceptions
The clinician should ask the patient...
what they know about osteoporosis and fractures 84% 93% 87%
about their views on the strength of their bones* 16% 73% 33%
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Table 3 (continued)
Statement Round 3
% of participants agreeing that each statement
was ‘essential in a time-limited consultation’
≤7 5% italics







their views of prescription medicine generally* 35% 53% 40%
if they have any concerns generally, or if anything is on their mind 81% 80% 81%
their knowledge, views and preferences about osteoporosis medicines (drug treatments) 84% 80% 83%
how important maintaining independence is to them 81% 67% 77%
Stage 5: Establishing shared decision-making preferences
The clinician should...
establish what involvement the patient would like to have in making decisions about medicines 68% 87% 73%†
ask if the patient would like to discuss medicine or lifestyle approaches first* 62% 53% 60%
Stage 6: Sharing information about the condition
The clinician should explain to the patient...
that osteoporosis means bones are weaker and may be likely to break (fracture) after a minor bump or
fall
100% 100% 100%
that osteoporosis does not give you physical symptoms (e.g. pain) unless you have broken a bone 81% 93% 85%
that keeping up a healthy lifestyle (not smoking, regular exercise) is important in maintaining bone
strength and health
97% 100% 98%
that if osteoporosis medication is taken regularly it will lower the risk of breaking bones in the future 97% 100% 98%
that their bone density scan results are only part of a picture of their bone strength 87% 93% 89%
that they are at increased risk of breaking bones, using simple numbers (e.g. they have a 30 in 100
chance of breaking a bone over the next 10 years)
84% 100% 89%
that finding osteoporosis is a good thing because we can do something about it 89% 100% 92%
what risk factors they may have for weaker bones 81% 100% 87%
that people with osteoporosis are more likely to break bones such as their wrist, hip or bones in the
spine
95% 100% 96%
that spinal fractures happenwhen the bone squashes down andmay cause pain and curving of the spine 81% 80% 81%
The clinician should...
ask the patient what they already know about how future broken bones could affect their life* 35% 67% 44%
use pictures or models to show how the condition affects the bone* 57% 60% 58%
show and explain the bone density scan results 95% 100% 96%
Stage 7: Sharing information about treatment—lifestyle and drugs
The clinician should explain…
how much the risk of broken bones is lowered with medicine, using simple numbers and pictures 73% 80% 75%†
that tablet medicine is usually recommended first, e.g. oral bisphosphonates 89% 93% 90%
that this medicine is recommended for osteoporosis or people with high fracture risk 100% 87% 96%
the aims and benefits of medicine, i.e. to strengthen bones and lower the chance of future broken bones 81% 100% 87%
that osteoporosis medicine does not make you feel better, and it is not possible to ‘feel’ stronger bones 62% 87% 69%†
what is involved in taking the medicine, including how long it will be taken for 100% 100% 100%
common or severe side effects 92% 100% 94%
that diet and physical activity are important in strengthening bone and have a complementary effect to
medicines
100% 100% 100%
that diet, physical activity and supplements cannot be viewed as a substitute for medicines as we do not
know that they work well enough to lower the risk of broken bones
76% 100% 83%
that medicines maintain bone strength and stop it from getting worse 81% 100% 87%




Arch Osteoporos           (2021) 16:58 Page 9 of 17    58 
Table 3 (continued)
Statement Round 3
% of participants agreeing that each statement
was ‘essential in a time-limited consultation’
≤7 5% italics







before discussing medicines, ask the patient if they have any concerns about their dental health* 68% 87% 73%
ask the patient what they knows about how lifestyle affects bone health* 43% 67% 50%
recommend calcium and/or vitamin D supplements as appropriate 100% 100% 100%
give general advice about avoiding falls if appropriate 78% 100% 85%
be able to discuss the benefits and risks of oral and intravenous bisphosphonates and denosumab
injection
N/A N/A N/A
discuss the choice of medicines with the patient in this appointment 84% 87% 85%
outline the risks and benefits of injectable medicines in this appointment, so that the patient can make
an informed decision about how they want to proceed
100% 100% 100%
give advice about stopping smoking and lowering alcohol intake (if appropriate) 81% 100% 87%
General
The first discussion about the benefits and risks of osteoporosis medicines is best undertaken in the
Fracture Liaison Service appointment
N/A N/A N/A
The discussion about the benefits and risks of osteoporosis medicines is best undertaken face-to-face N/A N/A N/A
Stage 8: Checking understanding and summarise
The clinician should check whether the patient…
understands what the medicine will achieve 89% 93% 90%
feels sure about the best choice of drug treatment (medicine) 78% 93% 83%
knows the benefits and risks 70% 93% 77%
is clear about which benefits and risks matter most to them 70% 93% 77%
has enough support to make an informed decision about osteoporosis drug treatment (medicine) 81% 87% 83%
is happy to take the recommended option, prefers not to take it or if they are still unsure 97% 100% 98%
feels that the recommended medicine is relevant to them to meet their goals 46% 73% 54%†
The clinician should…
accept the patient may have different views on risks and benefits of medicines 87% 100% 90%
check the patient’s knowledge of osteoporosis* 76% 73% 75%
check whether the patient has any concerns about the recommended medicine 92% 93% 92%
Stage 9: Discussing next steps
The clinician should…
explain what to do if the patient misses a dose of their medication 89% 100% 92%
explain how medication effectiveness is measured/monitored 81% 93% 85%
outline what will happen next in terms of follow-up (i.e. the patient will receive a telephone call
follow-up to find out how they are getting on with the medicine, and when this will be
100% 100% 100%
if appropriate, refer the patient on to other services, e.g. falls prevention clinic 89% 100% 92%
ask the patient what questions they have 89% 93% 90%
offer advice/onward referral if the patient has concerns about fracture symptoms, such as pain 87% 93% 89%
give the patient written information about osteoporosis 87% 100% 90%
give the patient a written copy of their individualised fracture risk, and risks and benefits of drug
treatment
84% 67% 79%
send the patient's GP a written copy of their individualised fracture risk, and risks and benefits of drug
treatment
95% 93% 94%
offer a further additional telephone consultation to review in 1–2 weeks time 78% 80% 79%
arrange a standard follow-up call (in 1–2 months time)* 76% 73% 75%
give the patient information to show their dentist if prescribed bisphosphonates 76% 87% 79%
95% 73% 89%
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their preference for discussing lifestyle or drug treatment first
were all identified as optional.
Stage 6: Sharing information about condition
Essential Patients/carers and clinicians both had high
agreement that it was essential for clinicians to explain
what osteoporosis is, its relationship with symptoms, the
individual risk factors a patient has, the consequences (in
terms of broken bones and potential spinal symptoms) and
the controllability of the condition. In addition, a state-
ment added as a result of a free-text comment, about be-
ing positive that identifying osteoporosis was a good
thing, so as to be able to ‘do something about it’, also
achieved high (92%) agreement.
Optional Using pictures or models to aid the explanation and
asking what patients already know about how broken bones
could affect their life were identified as optional.
Not relevant In Rounds 1 and 2, statements that described the
potential consequences of fracture (e.g. ‘the clinician should
explain that one in ten patients with a hip fracture will die
within 12 months of fracture’) were removed or amended.
Free-text comments by clinicians and patients/carers de-
scribed these statements as potentially gloomy and scary, with
the potential to contribute to patient loss of confidence. In
addition, explanatory statements related to the timing of oste-
oporosis (progresses slowly) and reassuring patients that there
is often no cause identified were rated of relatively lower
importance and removed.
Stage 7: Sharing information about drug and lifestyle
treatment
EssentialConsensus was gained in Round 2 that, aside from
oral bisphosphonates, clinicians should be able to discuss
the benefits and risks of intravenous bisphosphonate and
denosumab injections and that this discussion is best con-
ducted in a face-to-face consultation. Both patients/carers
and clinicians had high agreement with statements that the
discussion should include explanation of why medicine is
recommended, aims and benefits, common or severe side
effects, what is involved in taking the medicine and how
long it will be taken for. In terms of lifestyle management,
clinicians and patients/carers both rated highly discussion
about diet and supplements, physical activity, avoiding
falls, smoking cessation and alcohol reduction, if appropri-
ate. However, there was less agreement among patients/
carers than clinicians with the statement ‘that diet, physical
activity and supplements cannot be viewed as a substitute
for medicines as we do not know that they work well
enough to lower the risk of broken bones’ (76% vs 100%
respectively).
Two statements which fell below the threshold to include
in a time-limited consultation by patients/carers and clinicians
were deemed essential by the study team. First, a statement
relating to communicating fracture risk improvement with
Table 3 (continued)
Statement Round 3
% of participants agreeing that each statement
was ‘essential in a time-limited consultation’
≤7 5% italics







suggest that the patient considers the information and then rings a patient helpline (e.g. the Royal
Osteoporosis Society helpline/a local helpline) to discuss further
give contact details for where the patient can get hold of high quality information and support (e.g. the
Royal Osteoporosis Society)
100% 100% 100%
explain what information the GP will receive and when* 65% 80% 69%
ask the patient how they would like to receive further information (e.g. paper, by text, website)* 76% 73% 75%
explain who to contact in case of questions 87% 100% 90%
respect the patient's decision, and continue with providing written information, further contact details
in case of questions and explain about the communications the GP will receive.
100% 100% 100%
give the patient information about local support groups and services 89% 67% 83%
*Optional statements
†Deemed essential, with theoretical justification, following review by study team and experts, despite being below threshold
N/A not applicable, not included in Round 3 survey (consensus achieved at Round 2). For Round 1–2 results, see Supplementary Table 2
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Table 4 FLS consultation recommendations
Consultation stage FLS clinician should: Additional information
Greeting/introduction 1. Explain the aim of the appointment* and find out what the
patient is expecting from the appointment
*Aim includes investigating for osteoporosis, estimating risk of
fracture and considering steps to improve bone health/ re-
duce chance of further fractures
Gathering
information
2. Take a history, including information about the fracture*,
medical history**, fracture risk factors***, falls and lifestyle
behaviours****
*Including how the fracture happened and impact on life
**To identify causes of osteoporosis and contraindications to
medicines
***Such as smoking, family history, previous fractures,
alcohol, medical conditions, medications etc., back pain and
height loss (signs of vertebral fracture)
****General health and diet and calcium intake
3. Recommend, arrange and explain DXA*, spinal imaging
and blood tests if appropriate
*Including why DXA is recommended, what it involves and
how it will affect them
Considering
therapeutic options
4. Use national guidelines to decide which patients should be
offered drug treatment*
*While being aware of circumstances where fracture risk may
be underestimated. Do not offer oral bisphosphonates to
those with severe indigestion, problems swallowing or




5. Ask the patient what they already know and think about
osteoporosis, osteoporosis medicines and their concerns and
how important maintaining independence is
Establishing SDM
preferences
6. Establish what involvement the patient would like to have in




7. Show and explain bone density results* *In people who do not meet the densitometry definition for
osteoporosis, but are recommended treatment, explain that
bone density results are only part of a picture of their bone
strength, but that they are at increased risk of breaking bones.
Use simple numbers (e.g. they have a 30 in 100 chance of
breaking a bone over the next 10 years)
8. Explain what osteoporosis is*, the causes**, the
consequences*** and how it can be controlled****
*Osteoporosis means bones are weaker and may be likely to
break (fracture) after a minor bump or fall; does not give you
physical symptoms (e.g. pain) unless you break a bone
**Risk factors the patient has
***Mean that the patient may be more likely to break bones
such as wrist, hip or bones in the spine; spinal fractures
happen when the bone squashes down and may cause pain
and curving of the spine
****Explain finding osteoporosis is a good thing because we
can do something about it; keeping up a healthy lifestyle (not
smoking, regular exercise) is important in maintaining bone
strength and health; osteoporosis medication, if taken
regularly will lower the risk of breaking bones in the future)
Sharing information
about treatment
9. Discuss drug treatment* in a face-to-face FLS appointment,
if possible, including explanation of why the treatment is
recommended**, aims and benefits***, common or severe
side effects, what is involved in taking the medicine and how
long it will be taken for
*Oral or intravenous bisphosphonates, or denosumab
**Medicine is recommended for osteoporosis or people with
high fracture risk, tablet medicine is recommended first
***To strengthen bones, lower the chance of future broken
bones, prevent worsening, to play an important role in
maintaining independence and protecting the spine. Explain
how much the risk of broken bones is lowered with
medicine, using simple numbers and pictures. Explain that
osteoporosis medicine does not make you feel better, and it is
not possible to ‘feel’ stronger bones
10. Discuss the role of lifestyle management*, including diet
and supplements, physical activity, avoiding falls, smoking
cessation and alcohol reduction if appropriate
*Explain diet and physical activity are important in
strengthening bone and have a complementary effect to
medicines; explain diet, physical activity and supplements
cannot be viewed as a substitute for medicines as we do not





11. Check patient understanding* and ask about any concerns *About the benefits and risks, whether they are clear about
what matters to them and how the benefits are relevant to
their goals
   58 Page 12 of 17 Arch Osteoporos           (2021) 16:58 
medicine was deemed to be an essential component of commu-
nicating drug treatment benefit and conveying accurate drug
treatment expectations. Secondly, the statement that the clinician
‘should explain that osteoporosis medicine does not make you
feel better, and it is not possible to “feel” stronger bones’ only
achieved 62% patient/carer agreement, yet the study team, in
conjunction with expert input from a behavioural scientist, felt
that setting realistic drug treatment expectations was essential to
promote informed long-term adherence to medicines.
Optional Asking if the patient has concerns about their dental
health or knows how lifestyle affects bone health were iden-
tified as optional tasks.
Not relevant Being able to discuss hormone replacement ther-
apies and raloxifene and teriparatide injections was ranked as of
relatively lower importance, with free-text statements suggest-
ing that some respondents perceived ‘specialists’ (e.g. rheuma-
tologists) as being better placed to discuss these treatments
rather than FLS clinicians due to their unfamiliarity. Using
numeric scales to ask and quantify how much side effects mat-
ter, as recommended in the Ottawa Consult Decision Aid tem-
plate [28], was rated of relative lower importance and removed.
A number of statements focused on the amount of infor-
mation provided to patients about the side effects of medica-
tions (e.g. ‘explain only side effects the patient is most con-
cerned about’ and ‘explain all the side effects’). Apart from
‘explain common or severe side effects’, the statements were
scored as of relatively lower importance and were removed in
Rounds 1 and 2.
Stage 8: Checking understanding and summarising
Essential Tasks relating to checking patient understanding,
asking about any concerns and their decision to take treatment
were identified as essential.
Fifty-four percent of patients/carers and clinicians felt it
was essential for the clinician to ascertain whether the patient
felt the recommended medicine is relevant to their goals,
meaning this task fell below the threshold. The study group
felt this was an essential task, following discussion with the
study behavioural scientist, due to the importance of believing
drug treatment is necessary and personally relevant in foster-
ing informed medication adherence.
Optional Eliciting knowledge of osteoporosis at this stage was
identified as an optional task.
Not relevant In the context of a patient being unsure about
treatment, the statement ‘the clinician should suggest the pa-
tient discusses further with their GP’ was removed. Free-text
comments highlighted patient perceptions that GPs may have
limited knowledge about osteoporosis and practical chal-
lenges of accessing their GP.
Stage 9: Signposting next steps
Essential The following end of consultation tasks were iden-
tified as essential: explanation of how medication effective-
ness is measured and monitored; what to do if a dose of med-
ication is missed; arranging follow-up and onwards referrals
Table 4 (continued)
Consultation stage FLS clinician should: Additional information
12. Ask* if the patient is happy to take the recommended
option, prefers not to take it or if they are still unsure**
*Check they have enough support to make a decision about
medicine and if they are sure about the best choice
**Accept the patient may have different views on risk and
benefits and respect their decision
Signposting next
steps
13. Explain for patients starting treatment, how medication
effectiveness is measured andmonitored, what to do if a dose
of medication is missed and about follow-up*
*Explain that the patient will receive a telephone call follow-up
to find out how they are getting on with the medicine, and
when this will be
14. Arrange follow-up for patients who are unsure about
treatment and offer helpline to discuss further
15. Offer advice and onward referral for fracture management
and/or falls prevention if appropriate
16. Give the patient contact details and written information* *About osteoporosis, individualised fracture risk, risks and
benefits of treatment, information to give their dentist, advice
on local and national support groups
17. Ask what questions the patient has
18. Send GP a written copy of the patient’s individualised
fracture risk, and of risks and benefits of drug treatment
*Asterisks link recommendations with additional relevant information
DXA dual-energy X-ray absorptiometry, GP general practitioner, SDM shared decision-making
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as appropriate; giving written information and contact details;
asking what questions patients have; and sending the patient’s
GP a written copy of their individualised fracture risk and
risks and benefits of drug treatment. Clinicians had less agree-
ment than patients/carers with the statements that patients
should be given an individual copy of their fracture risk and
treatment risks and benefits and that they should be given
information about local support groups (67% vs 84% and
67% vs 89%, respectively).
Optional Asking the patient in what format they would like to
receive further information and explaining what information
the GP would receive and when were identified as optional.
Discussion
This Delphi exercise, informed by awide range of evidence and
theory, identified essential and optional content for the conduct
of the iFraPmodel clinician-patient consultation within the con-
text of FLSs. The findings have built on existing guidelines for
FLSs, by focusing on the consultation, and being able to pro-
vide specific detail about the content of explanations, particu-
larly those that help patients gain a clear understanding of their
condition and treatment and address their concerns.
We have identified that consultations need to cover a core
description of osteoporosis which must include a clear de-
scription of the condition and its ‘identity’, its causes, conse-
quences and controllability [37]. The most difficult area to
clarify from the results of this Delphi is related to the conse-
quences of osteoporosis. Explaining the consequences of os-
teoporosis has importance for conveying the necessity for
long-term medication which is important in promoting in-
formed adherence [38]. However, patient/carer (and some cli-
nician) responders articulated strong views in the free-text
comments about statements of this nature, describing informa-
tion about the potential for disability or death after fracture as
fear-inducing, and at odds with the need to provide positive
messages in the consultation. Our findings give practical guid-
ance on the content of explanations for patients who do not
meet bone mineral density definition of osteoporosis, but who
meet clinical guidelines for use of osteoporosis medicines, an
area of confusion for patients and clinicians alike [39].
The findings can be used to guide FLS clinicians in the
content of their discussion about drugs. By combining state-
ments from the NICE guidelines for medicine adherence and
osteoporosis guidelines, we have addressed a gap in existing
FLS Clinical Standards [4], which give information on which
medications should be offered or recommended but do not
give details about the content of discussion. The NICE guide-
lines for medicine adherence emphasise the need to take into
account perceptions (e.g. necessity beliefs and concerns) and
practicalities (e.g. capability and resources) that will affect
individuals’ motivation and ability to start and continue with
treatment [26]. Necessity beliefs relate to the extent to which
an individual perceives that medicine is relevant to them and
aligns with their personal goals [31]. Our results show the
clinicians felt that explaining side effects (addressing con-
cerns) and practical issues (how medicines are taken) was
more important than attending to necessity beliefs, perhaps
because of assumptions that patients are already convinced
that they need to take their medication. However, research
conducted across long-term conditions suggests that many
patients harbour doubts about the necessity for regular treat-
ment and these doubts are often linked to non-adherence.
Furthermore, clinicians did not appear to highly value giving
the patient a copy of their individualised fracture risk or writ-
ten information on the risks and benefits of medicines (as sent
to the GP), despite Clinical Standards recommending commu-
nications from the FLS are written in a style that can be un-
derstood by the patient and shared with them [19].
Our findings have revealed important insights regarding
FLS clinicians’ and patients’ views of the FLS clinician
role and scope of practice. The content for the Delphi
was derived from four sources: osteoporosis guidelines;
NICE guidelines relating to medicine adherence and pa-
tient experience; theories of shared decision-making and
medicine adherence; and emerging findings from the
iFraP-D study, which included views of stakeholders and
PPIE members. However, of the 12 osteoporosis guide-
lines included, only one was targeted specifically at the
FLS context [19]. The others were arguably intended for
a more medical audience [22, 23]. Previous qualitative re-
search has highlighted confusion over the roles of FLS
clinicians and other clinicians involved in osteoporosis
care [40, 41]. Statements relating to physical examination
were rated as being of relatively low importance by clini-
cians, and free-text comments supported the assertion that
some FLS clinicians do not perceive this as a core part of
their role. The findings provide clarity on the medications
that FLS clinicians feel more confident to discuss, namely
oral and intravenous bisphosphonates and denosumab.
Furthermore, we have identified patient/carer and FLS cli-
nician perceptions of the distinction between the role of the
FLS clinician and the primary care provider; participants
indicated that detailed discussion about commonly used
osteoporosis medications should take place within FLSs
and not in primary care, with the exception of hormone
replacement therapies (and issues related to the meno-
pause). As this study did not include primary care clini-
cians, further work is needed to determine their views on
these roles.
The findings give insight into difference between patient/
carers and clinicians in the areas of communication perceived
important. For example, while 100% of patients/carers felt
explaining the importance of lifestyle management was
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essential, three-quarters (76%) agreed that lifestyle manage-
ment cannot be viewed as a substitute for medicines. Previous
qualitative research has demonstrated the high value that pa-
tients place on lifestyle management and their frustration with
clinicians who may be perceived to overly focus on medica-
tions [42]. Three statements in the final essential content list
were scored highly by patients but not clinicians, relating to
asking about the impact of the fracture and providing written
information about fracture risk and information about support
groups. The reasons for clinician hesitancy in these areas
should be explored. Most of the statements where patient per-
centage agreement that a task was essential was > 20% lower
than clinicians were determined as optional, e.g. explaining
the limitations of FRAX, suggesting that these tasks could be
used with clinician discretion. Finally, the five statements
which were reconsidered as essential by the study team were
all rated higher by clinicians than patients, suggesting that
patients did not highly value important elements of shared
decision-making.
Strengths and limitations
Our study has a number of strengths and weakness. Strengths
include the broad range of guidelines, theory and empirical
evidence that underpinned the Delphi content, which is im-
portant for designing successful interventions [43].
Furthermore, we used robust methods, adhering to
methodologic criteria for reporting of Delphi studies [44].
The Delphi survey was underpinned by PPIE, with PAG
members contributing to survey design, analysis and interpre-
tation. Free-text comments provided by patient/carer partici-
pants described reworded statements as clear and understand-
able, recognising one of many positive outcomes associated
with PAG member contribution. Despite efforts to discuss
findings of Round 3 with PAG members, in the context of
COVID-19 where face-to-face meetings were not possible,
members did not feel confident using technologies (e.g. tele-
phone or remote conferencing software). Despite some drop
out between rounds, we managed to achieve our intended
sample size, with over-recruitment of patient/carer partici-
pants. Given that we had more patient/carer participants, we
had a strong patient representation; however, it was possible
for decision-making to be skewed by patient/carer views.
However, given many of the included items were
predetermined by professional guidelines, arguably the clini-
cal voice was strongly represented at the outset; furthermore,
we took into account clinician and patient/carer ratings sepa-
rately. Most clinician participants were FLS and osteoporosis
specialist nurses, representative of secondary care FLSs [2]
and reflecting the clinician groups that will use the iFraP in-
tervention. The lack of other clinician groups (e.g. primary
care clinicians, physician champions, endocrinologists, rheu-
matologists, internal medicine) participating in the survey
may narrow the focus and limit generalisability of the find-
ings; however, these other professional groups were represented
in the study stakeholder group and in other iFraP-D-linked stud-
ies (e.g. focus group with primary care clinicians). Recruitment
via the ROS and the use of an online survey meant that our
patient/carer sample may have more digital literacy and possibly
vary from the general population. However, we did recruit pa-
tient participants that are broadly representative of those attend-
ing FLSs [2], with awide range of ages, up to the age bracket 81–
90. In Round 2, ratings were generally high (all combined mean
scores ≥ 4), meaning that although some items fell in the lowest
quartile and were therefore removed, they were still deemed
important. However, we have been careful when discussing
statements that were removed, to indicate that these were rated
‘relatively’ low. The ROS FLS Clinical Standards included in
our synthesis [19] have been updated since we conducted our
research [4]. However, we do not feel that this would have con-
siderably changed our Delphi content because these Clinical
Standards did not change significantly in the update. However,
other recently published guidance includes an algorithm to iden-
tify and treat very high-risk patients with anabolic drugs first line
[45], which has implications for our findings given that we ex-
cluded discussion of teriparatide at Round 2 and may mean that
knowledge of a wider range of drug treatments should be con-
sidered ‘core’ FLS activity. Finally, we incorporated an addition-
al step after Round 3 to review optional statements and re-
classify items as essential, with appropriate theoretical justifica-
tion. While this could be argued to undermine the process of
consensus, it is a well-accepted methodological step within
Delphi to refine outputs, based on further expert views and theory
[35, 36], and resulted in re-classification of less than 6% of
Round 3 statements.
These findings have immediate implications for clinical
practice through establishing more clearly defined tasks for
FLS clinicians. Within iFraP, these findings will be synthe-
sised with findings from other aspects of the iFraP-D study
(including stakeholder workshops, focus groups with patients
and clinicians, usual care survey) to guide iFraP intervention
development, and specifically the design of the CDST and
content of the clinician training, and training manual.
Since this study has been conducted, the COVID-19 pan-
demic has resulted in significant changes to clinical practice.
For the most part, this does not change our recommendations,
with the exception of our recommendation that discussion
about risks and benefits of medicines is best undertaken
face-to-face. While it may not be practicable to hold face-to-
face consultations routinely for some time, further research is
needed to understand the impact of consulting remotely on
patient and clinical outcomes [46]. We have reported detailed
recommendations to guide explanations of osteoporosis and
osteoporosis medicines, but some gaps remain. Further work
with stakeholders is needed to address important areas, e.g. the
explanation of bone density results.
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Conclusion
This Delphi consensus exercise summarised for the first time
patient/carer and clinician views regarding important content
for the clinician-patient consultations in FLSs. The findings
have been summarised into 18 practical recommendations
which will be implemented in the iFraP consultation and also
will be of wider use in training FLS clinicians and informing
future iterations of FLS Clinical Standards.
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